MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering.
The offering consists of common stock and accompanying Series C and Series D warrants, priced at $3.10 per unit, with gross proceeds expected to total approximately $8.1 million before fees and expenses. MetaVia said the funds will be used for working capital and to advance its clinical pipeline, including the development of its obesity treatment candidate DA-1726. The underwriters were also granted a 45-day option to purchase additional shares and warrants.
On the day of the announcement, MTVA opened sharply lower, fell to intraday lows near $3.30, and traded significantly below its previous close of $5.58. The stock trades on the Nasdaq.
Trading volume spiked well above recent averages, highlighting heightened selling pressure following the capital raise announcement.
MetaVia's 52-week range is approximately $3.10 to $25.20, underscoring significant volatility tied to financing activity and clinical-stage biotech risk.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.